315 related articles for article (PubMed ID: 27545815)
1. Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.
Poggio F; Lambertini M; Blondeaux E; Vaglica M; Levaggi A; Pronzato P; Del Mastro L
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1153-61. PubMed ID: 27545815
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
[TBL] [Abstract][Full Text] [Related]
3. Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer.
Litsas G
Clin J Oncol Nurs; 2011 Dec; 15(6):674-81. PubMed ID: 22119979
[TBL] [Abstract][Full Text] [Related]
4. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Scott SM; Brown M; Come SE
Expert Opin Drug Saf; 2011 Sep; 10(5):819-26. PubMed ID: 21699443
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
Oakman C; Moretti E; Santarpia L; Di Leo A
Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.
Ishida N; Araki K; Sakai T; Kobayashi K; Kobayashi T; Fukada I; Hosoda M; Yamamoto M; Ichinokawa K; Takahashi S; Iwase T; Ito Y; Yamashita H
Breast Cancer; 2016 Jul; 23(4):617-23. PubMed ID: 25896598
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.
Kabos P; Borges VF
Expert Opin Pharmacother; 2010 Apr; 11(5):807-16. PubMed ID: 20151846
[TBL] [Abstract][Full Text] [Related]
8. The role of fulvestrant in endometrial cancer.
Bogliolo S; Cassani C; Dominoni M; Orlandini A; Ferrero S; Iacobone AD; Viazzo F; Venturini PL; Spinillo A; Gardella B
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):537-544. PubMed ID: 27696906
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy.
Heo MH; Kim HK; Lee H; Kim JY; Ahn JS; Im YH; Park YH
Korean J Intern Med; 2019 Sep; 34(5):1100-1106. PubMed ID: 29540055
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
Croxtall JD; McKeage K
Drugs; 2011 Feb; 71(3):363-80. PubMed ID: 21319872
[TBL] [Abstract][Full Text] [Related]
11. [Fulvestrant (Faslodex®) for hormone sensitive breast cancer. A review].
Nagykálnai T; Landherr L; Laczó I; Pikó B
Magy Onkol; 2015 Sep; 59(3):251-7. PubMed ID: 26339914
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
Wang J; Xu B; Wang W; Zhai X; Chen X
Breast Cancer Res Treat; 2018 Oct; 171(3):535-544. PubMed ID: 29974356
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of the clinical efficacy and safety of fulvestrant in heavily pretreated patients with hormone-receptor positive metastatic breast cancer-a single-institution experience].
Hattori M; Horio A; Sawaki M; Kondo N; Fujita T; Ushio A; Gondo N; Idota A; Ichikawa M; Iwata H
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2535-8. PubMed ID: 24335365
[TBL] [Abstract][Full Text] [Related]
16. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Harichand-Herdt S; Zelnak A; O'Regan R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
[TBL] [Abstract][Full Text] [Related]
17. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of fulvestrant for the treatment of metastatic breast cancer.
Soleja M; Raj GV; Unni N
Expert Opin Pharmacother; 2019 Oct; 20(15):1819-1829. PubMed ID: 31486688
[No Abstract] [Full Text] [Related]
20. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.
Buzdar AU
Drugs Today (Barc); 2004 Sep; 40(9):751-64. PubMed ID: 15538548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
